Citation Impact
Citing Papers
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
2017 Standout
Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma
2013
Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study
2008
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
2016 Standout
Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma
2010 StandoutScience
Guidelines for the welfare and use of animals in cancer research
2010 Standout
Co-incidence of RCC-susceptibility polymorphisms with HIF cis-acting sequences supports a pathway tuning model of cancer
2019 StandoutNobel
Hallmarks of Cancer: The Next Generation
2011 Standout
Intracerebral Human Regulatory T Cells: Analysis of CD4+CD25+FOXP3+ T Cells in Brain Lesions and Cerebrospinal Fluid of Multiple Sclerosis Patients
2011
Stromal fibroblasts in cancer initiation and progression
2004 StandoutNature
TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use
2009 Standout
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits
2009 Standout
Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines
2006 Standout
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
Complementary and alternative medicine: use and disclosure in radiation oncology community practice
2010 Standout
Final results of EFC6663: A multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia
2015
Epidermal growth factor receptor mutations in lung cancer
2007 Standout
Regulatory T Cells in Cancer
2010
Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation
2010
VHL and p53: Tumor Suppressors Team Up to Prevent Cancer
2006 StandoutNobel
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
2016 Standout
HIF-1α Induces Genetic Instability by Transcriptionally Downregulating MutSα Expression
2005 StandoutNobel
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for High-Risk Breast Cancer
2003
CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis
2006
A novel mouse model of hepatocarcinogenesis triggered by AID causing deleterious p53 mutations
2008 StandoutNobel
Cancer genes and the pathways they control
2004 Standout
<i>TP53</i> Status and Response to Chemotherapy in Breast Cancer
2008
Inflammation and Colon Cancer
2010 Standout
Blinded by the Light: The Growing Complexity of p53
2009 Standout
Immunopathology of multiple sclerosis
2015 Standout
Graft-versus-host disease
2009 Standout
Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial
2008
Baffled by Bafilomycin: An Anticancer Agent That Induces Hypoxia-Inducible Factor-1α Expression
2006 StandoutNobel
The Emerging Hallmarks of Cancer Metabolism
2016 Standout
Cancer immunotherapy comes of age
2011 StandoutNature
The cancer stem cell: premises, promises and challenges
2011 Standout
Eicosanoids and cancer
2010 Standout
Modulation of EZH2 expression in T cells improves efficacy of anti–CTLA-4 therapy
2018 StandoutNobel
Pancreatic Cancer
2010 Standout
Paul Ehrlich's magic bullet concept: 100 years of progress
2008 Standout
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
2011 StandoutNobel
Immunity to fungal infections
2011 Standout
Organ‐specific profiles of genetic changes in cancers caused by activation‐induced cytidine deaminase expression
2008 StandoutNobel
FcRn: the neonatal Fc receptor comes of age
2007 Standout
How does DNA break during chromosomal translocations?
2011
Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
2009 StandoutNobel
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication
2011 StandoutNobel
Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy
2023 StandoutNobel
Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America
2014 Standout
Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms
2012
Prevention of High-Dose Chemotherapy–Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition
2006 Standout
Prevention and Treatment of Cancer-Related Infections
2012
Stimulation of the Glucocorticoid-Induced TNF Receptor Family-Related Receptor on CD8 T Cells Induces Protective and High-Avidity T Cell Responses to Tumor-Specific Antigens
2010 StandoutNobel
Integrated NY-ESO-1 antibody and CD8+T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
2011 StandoutNobel
Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America
2011 Standout
Follicular lymphoma in situ: clinical implications and comparisons with partial involvement by follicular lymphoma
2011
Polymorphisms in the chemokine (C-X-C motif) ligand 10 are associated with invasive aspergillosis after allogeneic stem-cell transplantation and influence CXCL10 epression in monocyte-derived dendritic cells
2007
Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group
2008 Standout
Mutated kinases as targets for cancer drugs
2005
Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study
2005
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
2016 Standout
Overview of monoclonal antibodies in cancer therapy: present and promise
2005
Phase II Study of Flavopiridol in Relapsed Chronic Lymphocytic Leukemia Demonstrating High Response Rates in Genetically High-Risk Disease
2009
Spontaneous Transformation of Cultured Mouse Bone Marrow–Derived Stromal Cells
2006 StandoutNobel
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
Alemtuzumab for patients with chronic lymphocytic leukaemia
2012
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
2005 StandoutScience
Combination therapy strategies for improving PD‐1 blockade efficacy: a new era in cancer immunotherapy
2017 StandoutNobel
Therapeutic antibodies: their mechanisms of action and the pathological findings they induce in toxicity studies
2015
Evolutionary Comparison of the Mechanism of DNA Cleavage with Respect to Immune Diversity and Genomic Instability
2012 StandoutNobel
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
2016 Standout
Works of Manfred Hensel being referenced
Tandem high-dose chemotherapy in high-risk primary breast cancer: A multivariate analysis and a matched-pair comparison with standard-dose chemotherapy
2001
Complementary and alternative medicine in patients with chronic lymphocytic leukemia
2008
Level of CD 20-expression and Efficacy of Rituximab Treatment in Patients with Resistant or Relapsing B-cell Prolymphocytic Leukemia and B-cell Chronic Lymphocytic Leukemia
2002
Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab
2007
The bcl-2/IgH rearrangement in a population of 204 healthy individuals: Occurrence, age and gender distribution, breakpoints, and detection method validity
2005
Gastrointestinal stromal tumours and their response to treatment with the tyrosine kinase inhibitor imatinib
2004
Effect of tetravalent bispecific CD19×CD3 recombinant antibody construct and CD28 costimulation on lysis of malignant B cells from patients with chronic lymphocytic leukemia by autologous T cells
2004
P53 is the strongest predictor of survival in high‐risk primary breast cancer patients undergoing high‐dose chemotherapy with autologous blood stem cell support
2002
Disease activity and pretreatment, rather than hypogammaglobulinaemia, are major risk factors for infectious complications in patients with chronic lymphocytic leukaemia
2003
Subcutaneous Campath-1H (Alemtuzumab) in Fludarabine-Refractory Cll: Interim Analysis of the CLL2h Study of the German Cll Study Group (GCLLSG).
2004
DHAP in combination with rituximab vs DHAP alone as salvage treatment for patients with relapsed or refractory diffuse large B-cell lymphoma: a matched-pair analysis
2006
TP53 Mutation and Survival in Chronic Lymphocytic Leukemia
2010
Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group
2009
Specific recruitment of regulatory T cells into the CSF in lymphomatous and carcinomatous meningitis
2007